Refer your friends!

Study Details

The investigational drug in this research study is being developed for the potential treatment of obesity and potentially type 1 and 2 diabetes mellitus. Tirzepatide is an injectable prescription drug that has been approved by the FDA for chronic weight management in doses up to 15 mg once weekly, in addition to diet, exercise, and oral medications. The use of tirzepatide in combination with the study drug in this study is investigational. 

Fortrea Dallas, TX is recruiting for:

-Healthy Men and Women of non-childbearing potential, age 18-65

-Body Mass Index between 27-40

-Study involves 2 separate stays totaling 9 nights at our clinic & 21 follow-up visits

-Compensation up to $18,895 may be provided for time and participation

-Refer a friend to receive $400 per qualified referral

Additional Details

B1b:

Check-in: May 27

Check-out: May 31

Outpatient visits: Jun 4, 11, 18, 25, Jul 2, 9, 16, 23, 30, Aug 6, 13, 20, 27, Sep 3

Check-in: Sep 10

Check-out: Sep 15

Outpatient visits: Sep 17, 24, Oct 1, 8, 15, Nov 5, 19

OR

B2a:

Check-in: Jun 8

Check-out: Jun 12

Outpatient visits: Jun 16, 23, 30, Jul 7, 14, 21, 28, Aug 4, 11, 18, 25, Sep 1, 8, 15

Check-in: Sep 22

Check-out: Sep 27

Outpatient visits: Sep 29, Oct 6, 13, 20, 27, Nov 17, Dec 1